前列腺癌前哨淋巴结活检:共识专家组会议报告
通过两轮德尔菲调查和16位专家共识会议,对150条陈述进行投票,91条(61%)达成共识;专家认为扩大淋巴结清扫仍是金标准,前哨淋巴结检测应与之联合,至少用于中高危前列腺癌患者,低危患者中的作用尚不明确。
要点
- 扩大淋巴结清扫结果仍被视为金标准,前哨淋巴结检测应与之联合,至少用于中高危前列腺癌患者。
- 前哨淋巴结检测在低危前列腺癌中的作用尚不明确。
- 未来研究应包含肿瘤学终点,如扩大淋巴结清扫模板外的阳性淋巴结数、前哨淋巴结操作的假阴性和假阳性率及无复发生存率。
核心结论
- 专家对前哨淋巴结检测在前列腺癌中的多数基本陈述达成共识,该共识报告将为进一步研究设计提供基础。
- 专家组识别了前哨淋巴结检测在前列腺癌及其日常实践中应用的证据和知识缺口,共识陈述信息可用于指导进一步研究。
研究设计与样本
- 采用两轮德尔菲调查,随后于2016年2月召开16位专家共识会议。
- 采用研究与发展项目/加州大学洛杉矶分校适宜性方法对9个领域的150条陈述进行一致性投票。
- 使用基于四分位间距并校正对称性评分的不一致指数评估共识与非共识。
主要发现
- 150条陈述中91条(61%)达成共识。
- 关于未来前哨淋巴结活检临床试验结局指标的共识率高达89%。
- 关于示踪剂技术的共识仅在47%的陈述中达成,反映该领域需进一步研究和标准化。
关键数值与推荐
- 扩大淋巴结清扫结果仍被视为金标准,前哨淋巴结检测应与之联合,至少用于中高危前列腺癌患者。
- 前哨淋巴结检测在低危前列腺癌中的作用尚不明确。
- 未来研究应包含肿瘤学终点:扩大淋巴结清扫模板外的阳性淋巴结数、前哨淋巴结操作的假阴性和假阳性率及无复发生存率。
临床怎么用
- 专家组认为扩大淋巴结清扫结果仍为金标准,前哨淋巴结检测应与之联合,至少用于中高危前列腺癌患者。
- 专家组指出前哨淋巴结检测在低危前列腺癌中的作用尚不明确。
- 共识陈述信息可用于指导进一步研究。
局限性
- 现有文献证据水平低。
- 专家组主要由前哨淋巴结活检使用者组成。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore the evidence and knowledge gaps in sentinel node biopsy (SNB) in prostate cancer through a consensus panel of experts. METHODS: A two-round Delphi survey among experts was followed by a consensus panel meeting of 16 experts in February 2016. Agreement voting was performed using the research and development project/University of California, Los Angeles Appropriateness Methodology on 150 statements in nine domains. The disagreement index based on the interpercentile range, adjusted for symmetry score, was used to assess consensus and non-consensus among panel members. RESULTS: Consensus was obtained on 91 of 150 statements (61%). The main outcomes were: (1) the results from an extended lymph node dissection (eLND) are still considered the 'gold standard', and sentinel node (SN) detection should be combined with eLND, at least in patients with intermediate- and high-risk prostate cancer; (2) the role of SN detection in low-risk prostate cancer is unclear; and (3) future studies should contain oncological endpoints as number of positive nodes outside the eLND template, false-negative and false-positive SN procedures, and recurrence-free survival. A high rate of consensus was obtained regarding outcome measures of future clinical trials on SNB (89%). Consensus on tracer technology was only obtained in 47% of statements, reflecting a need for further research and standardization in this area. The low-level evidence in the available literature and the composition of mainly SNB users in the panel constitute the major limitations of the study. CONCLUSIONS: Consensus on a majority of elementary statements on SN detection in prostate cancer was obtained.; therefore, the results from this consensus report will provide a basis for the design of further studies in the field. A group of experts identified evidence and knowledge gaps on SN detection in prostate cancer and its application in daily practice. Information from the consensus statements can be used to direct further studies.
引用
- van der Poel HG, Wit EM, Acar C, et al. Sentinel node biopsy for prostate cancer: report from a consensus panel meeting. BJU Int. 2017. PMID: 28188689. doi:10.1111/bju.13810
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。